Hyderabad-based COVID-19 vaccine maker Bharat Biotech announced on April 29 that Covaxin would be available at the rate of Rs 400 per dose to state governments.
The company had earlier set Covaxin’s price at Rs 600 per dose for state governments, slashed by Rs 200 per dose given the enormous challenges the second wave of the pandemic has posed for public healthcare systems.
Thus, Bharat Biotech’s Covaxin will be available to the Centre at Rs 150 per dose, to states at Rs 400 per dose, and private laboratories at Rs 1,200 per dose.
Notably, Bharat Biotech’s announcement came a day after Adar Poonawalla, the CEO of the Serum Institute of India, manufacturing Oxford-AstraZeneca’s COVID-19 vaccine candidate Covishield, announced that the price of the vaccine would be reduced by Rs 100 for state governments.
Earlier, SII had set a price of Rs 400 per dose of Covishield for states, which, on April 28, was reduced to Rs 300 per dose. Poonawalla tweeted: “I hereby reduce the price to the states from Rs 400 to Rs 300 per dose, effective immediately; this will save thousands of crores of state funds in the future. This will enable more vaccinations and save countless lives (sic).”